Titre :

COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022.

Auteur(s) :

Jeantin, L. [Auteur]
Januel, E. [Auteur]
Labauge, P. [Auteur]
Maillart, E. [Auteur]
De Seze, J. [Auteur]
Zephir, Helene [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Pelletier, J. [Auteur]
Kerschen, P. [Auteur]
Biotti, D. [Auteur]
Heinzlef, O. [Auteur]
Guilloton, L. [Auteur]
Bensa, C. [Auteur]
Théaudin, M. [Auteur]
Vukusic, S. [Auteur]
Casez, O. [Auteur]
Maurousset, A. [Auteur]
Laplaud, D. [Auteur]
Berger, E. [Auteur]
Lebrun-Frenay, C. [Auteur]
Bourre, B. [Auteur]
Branger, P. [Auteur]
Stankoff, B. [Auteur]
Clavelou, P. [Auteur]
Thouvenot, E. [Auteur]
Manchon, E. [Auteur]
Moreau, T. [Auteur]
Sellal, F. [Auteur]
Zedet, M. [Auteur]
Papeix, C. [Auteur]
Louapre, C. [Auteur]

Titre de la revue :

Multiple Sclerosis Journal

Nom court de la revue :

Mult Scler

Numéro :

30

Pagination :

13524585231218149

Éditeur :

SAGE Journals

Date de publication :

2024-01-23

ISSN :

1477-0970

Mot(s)-clé(s) en anglais :

Multiple sclerosis
SARS-CoV-2
vaccination
COVID-19
COVID-19 vaccines
COVID-19 testing

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Background: Epidemiologic studies on coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (pwMS) have focused on the first waves of the pandemic until early 2021. Objectives: We aimed to extend these ...
Lire la suite >Background: Epidemiologic studies on coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (pwMS) have focused on the first waves of the pandemic until early 2021. Objectives: We aimed to extend these data from the onset of the pandemic to the global coverage by vaccination in summer 2022. Methods: This retrospective, multicenter observational study analyzed COVISEP registry data on reported COVID-19 cases in pwMS between January 2020 and July 2022. Severe COVID-19 was defined as hospitalization or higher severity. Results: Among 2584 pwMS with confirmed/highly suspected COVID-19, severe infection rates declined from 14.6% preomicron wave to 5.7% during omicron wave (p < 0.001). Multivariate analysis identified age (odds ratio (OR) = 1.43, 95% confidence interval (CI) = [1.25–1.64] per 10 years), male sex (OR = 2.01, 95% CI = [1.51–2.67]), obesity (OR = 2.36, 95% CI = [1.52–3.68]), cardiac comorbidities (OR = 2.36, 95% CI = [1.46–3.83]), higher Expanded Disability Status Scale (EDSS) scores (OR = 2.09, 95% CI = [1.43–3.06] for EDSS 3–5.5 and OR = 4.53, 95% CI = [3.04–6.75] for EDSS ⩾6), and anti-CD20 therapies (OR = 2.67, 95% CI = [1.85–3.87]) as risk factors for COVID-19 severity. Vaccinated individuals experienced less severe COVID-19, whether on (risk ratio (RR) = 0.64, 95% CI = [0.60–0.69]) or off (RR = 0.32, 95% CI = [0.30–0.33]) anti-CD20. Discussion: In pwMS, consistent risk factors were anti-CD20 therapies and neurological disability, emerging as vital drivers of COVID-19 severity regardless of wave, period, or vaccination status.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172

Date de dépôt :

2024-05-15T21:47:48Z
2024-07-03T07:34:17Z